RT Book, Section
A1 Krakow, Elizabeth F.
A1 Fraser, Graeme
A2 McKean, Sylvia C.
A2 Ross, John J.
A2 Dressler, Daniel D.
A2 Brotman, Daniel J.
A2 Ginsberg, Jeffrey S.
SR Print(0)
ID 56208532
T1 Chapter 179. Hematologic Malignancies
T2 Principles and Practice of Hospital Medicine
YR 2012
FD 2012
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-160389-8
LK accessmedicine.mhmedical.com/content.aspx?aid=56208532
RD 2024/04/19
AB What  are  the  “classic”  clinical  and  basic  laboratory  features  of  each  of  the  common  hematologic  malignancies?  (“How  do  I  prove  the  diagnosis?”)What  is  the  natural  history  of  each  disease  entity  without  therapy?What  is  the  goal  of  treatment  for  each  disease  entity  (cure,  prolongation  of  survival,  or  purely  palliation)?Which  modalities  may  be  employed  for  each  disease  entity  (chemotherapy,  immunotherapy,  radiation,  stem  cell  transplant)?What  is  the  prognosis  with  therapy?  How  can  the  prognosis  estimate  be  refined?What  needs  to  be  done  to  prepare  the  patient  for  therapy  (to  communicate  risks  and  benefits  and  to  reduce  toxicity)?How  do  we  assess  the  response?How  do  we  monitor  the  patient  after  completion  of  therapy,  both  early  on  (for  relapse)  and  later  (for  delayed  toxicities  of  therapy)?